CA2896939C - Treatment of hyperhidrosis - Google Patents
Treatment of hyperhidrosis Download PDFInfo
- Publication number
- CA2896939C CA2896939C CA2896939A CA2896939A CA2896939C CA 2896939 C CA2896939 C CA 2896939C CA 2896939 A CA2896939 A CA 2896939A CA 2896939 A CA2896939 A CA 2896939A CA 2896939 C CA2896939 C CA 2896939C
- Authority
- CA
- Canada
- Prior art keywords
- itpr2
- use according
- nucleic acid
- acid molecule
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008454 Hyperhidrosis Diseases 0.000 title claims description 38
- 230000037315 hyperhidrosis Effects 0.000 title claims description 15
- 238000011282 treatment Methods 0.000 title abstract description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 49
- 230000035900 sweating Effects 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 3
- 108020004999 messenger RNA Proteins 0.000 claims description 41
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 210000000106 sweat gland Anatomy 0.000 claims description 13
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 5
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 claims description 5
- 238000007385 chemical modification Methods 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 230000003248 secreting effect Effects 0.000 claims description 4
- 238000007910 systemic administration Methods 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 229920000962 poly(amidoamine) Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000037317 transdermal delivery Effects 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- -1 stick Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 7
- 230000004853 protein function Effects 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 101000975421 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 2 Proteins 0.000 abstract 2
- 102100024037 Inositol 1,4,5-trisphosphate receptor type 2 Human genes 0.000 abstract 2
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 70
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 69
- 239000004055 small Interfering RNA Substances 0.000 description 38
- 210000004243 sweat Anatomy 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 14
- 230000003828 downregulation Effects 0.000 description 12
- 210000000245 forearm Anatomy 0.000 description 10
- 238000005259 measurement Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 101150059391 Itpr2 gene Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 101000975401 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 3 Proteins 0.000 description 3
- 208000008017 Hypohidrosis Diseases 0.000 description 3
- 102100024035 Inositol 1,4,5-trisphosphate receptor type 3 Human genes 0.000 description 3
- 206010002512 anhidrosis Diseases 0.000 description 3
- 230000037001 anhydrosis Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical group O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 2
- 101100126626 Drosophila melanogaster Itpr gene Proteins 0.000 description 2
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 2
- 101000975428 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 1 Proteins 0.000 description 2
- 102100024039 Inositol 1,4,5-trisphosphate receptor type 1 Human genes 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229940015042 glycopyrrolate Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102100039601 ARF GTPase-activating protein GIT1 Human genes 0.000 description 1
- 102100039602 ARF GTPase-activating protein GIT2 Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 101150017002 CD44 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102100032216 Calcium and integrin-binding protein 1 Human genes 0.000 description 1
- 101710103933 Calcium and integrin-binding protein 1 Proteins 0.000 description 1
- OYPRJOBELJOOCE-RKEGKUSMSA-N Calcium-47 Chemical compound [47Ca] OYPRJOBELJOOCE-RKEGKUSMSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 1
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000888659 Homo sapiens ARF GTPase-activating protein GIT1 Proteins 0.000 description 1
- 101000888642 Homo sapiens ARF GTPase-activating protein GIT2 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 108091008585 IP3 receptors Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- JGDITNMASUZKPW-UHFFFAOYSA-K aluminium trichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Al](Cl)Cl JGDITNMASUZKPW-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000003730 sympathetic denervation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361748592P | 2013-01-03 | 2013-01-03 | |
| US61/748,592 | 2013-01-03 | ||
| PCT/SE2013/051508 WO2014107124A1 (en) | 2013-01-03 | 2013-12-13 | Treatment of hyperhidrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2896939A1 CA2896939A1 (en) | 2014-07-10 |
| CA2896939C true CA2896939C (en) | 2022-07-12 |
Family
ID=51062371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2896939A Active CA2896939C (en) | 2013-01-03 | 2013-12-13 | Treatment of hyperhidrosis |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9809820B2 (enExample) |
| EP (1) | EP2958572B1 (enExample) |
| JP (1) | JP6242402B2 (enExample) |
| CN (1) | CN105025903B (enExample) |
| CA (1) | CA2896939C (enExample) |
| WO (1) | WO2014107124A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2958572B1 (en) * | 2013-01-03 | 2019-10-23 | Hidros Therapeutics International AB | Treatment of hyperhidrosis |
| AU2016236521B2 (en) | 2015-03-20 | 2019-03-07 | Unilever Global Ip Limited | Antiperspirant composition |
| CN110643598A (zh) * | 2018-06-26 | 2020-01-03 | 煌鼎科技有限公司 | 促进皮肤凹疤愈合及毛孔收缩的酵母dna原料制法 |
| WO2024104663A1 (en) | 2022-11-16 | 2024-05-23 | Unilever Ip Holdings B.V. | Method of reducing malodour |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019055D0 (en) | 2000-08-03 | 2000-09-27 | Unilever Plc | Antiperspirant and deodorant products and methods for their use |
| KR20050057086A (ko) | 2002-08-28 | 2005-06-16 | 홀리스-에덴 파마슈티칼즈, 인코포레이티드 | 치료적 처치 방법 |
| EP1606406B2 (en) * | 2003-03-21 | 2013-11-27 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| WO2007046102A2 (en) * | 2005-10-19 | 2007-04-26 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
| US8618160B2 (en) * | 2007-10-18 | 2013-12-31 | Rose U | Topical glycopyrrolate formulations |
| WO2010065567A2 (en) | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
| AU2010282273A1 (en) * | 2009-08-14 | 2012-03-15 | Allergan, Inc. | Methods of treating cancer using tachykinin retargeted endopeptidases |
| US20120207704A1 (en) | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases |
| EP2958572B1 (en) * | 2013-01-03 | 2019-10-23 | Hidros Therapeutics International AB | Treatment of hyperhidrosis |
-
2013
- 2013-12-13 EP EP13870321.0A patent/EP2958572B1/en active Active
- 2013-12-13 WO PCT/SE2013/051508 patent/WO2014107124A1/en not_active Ceased
- 2013-12-13 US US14/759,153 patent/US9809820B2/en active Active
- 2013-12-13 CA CA2896939A patent/CA2896939C/en active Active
- 2013-12-13 CN CN201380069414.3A patent/CN105025903B/zh active Active
- 2013-12-13 JP JP2015551659A patent/JP6242402B2/ja active Active
-
2017
- 2017-09-19 US US15/709,249 patent/US10633661B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10633661B2 (en) | 2020-04-28 |
| JP6242402B2 (ja) | 2017-12-06 |
| US20160122770A1 (en) | 2016-05-05 |
| US20180044682A1 (en) | 2018-02-15 |
| EP2958572B1 (en) | 2019-10-23 |
| CN105025903A (zh) | 2015-11-04 |
| EP2958572A1 (en) | 2015-12-30 |
| CA2896939A1 (en) | 2014-07-10 |
| US9809820B2 (en) | 2017-11-07 |
| JP2016505617A (ja) | 2016-02-25 |
| WO2014107124A1 (en) | 2014-07-10 |
| CN105025903B (zh) | 2018-04-13 |
| EP2958572A4 (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11957931B2 (en) | Compositions and methods for treating vitiligo | |
| AU2010217213B2 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| US10633661B2 (en) | Treatment of hyperhidrosis | |
| EA018101B1 (ru) | Способы лечения кожных язв | |
| Shibata et al. | Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy | |
| JP2021080271A (ja) | 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物 | |
| US9234200B2 (en) | Oligonucleotide, glucocorticoid sensitivity enhancer, pharmaceutical composition, and expression vector | |
| AU2019375245B2 (en) | Composition for preventing or treating atopic dermatitis comprising skin-penetrating nucleic acid complex as effective component | |
| US20220249511A1 (en) | Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders | |
| US20240115546A1 (en) | Agent for preventing or ameliorating pruritus | |
| WO2021252261A1 (en) | Compositions and methods for hair follicle regeneration | |
| US20190083455A1 (en) | Methods and compositions for the modulation of beta-endorphin levels | |
| US20240307283A1 (en) | Compositions and methods for decreasing pigmentation | |
| WO2024165876A2 (en) | Compositions and methods of using c/ebp alpha sarna | |
| JP2023111535A (ja) | セマフォリン３ａ発現促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180917 |
|
| EEER | Examination request |
Effective date: 20180917 |